Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Filings indexed 1,576 across all filing types
Latest filing 2026-05-19 Interim / Quarterly Rep…
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
QUARTERLY REPORT
Interim / Quarterly Report Q1 2026
2026-05-19 English
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
Director's Dealing
2026-03-18 English
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
Director's Dealing
2026-03-18 English
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
Director's Dealing
2026-03-18 English
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
Director's Dealing
2026-03-18 English
8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a Warrant Agreement between Oramed Pharmaceuticals Inc. and Scilex Holding Company. It details the terms of the warrant, exercise price, and related conditions. There are no financial statements or quarterly/yearly financial results presented, nor is this a transcript, proxy, or governance document. The document is not an announcement of a report publication but a standalone filing about a financing-related agreement. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2026-02-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.